http://www.raredr.com/news/numedii-advisory-board-ipf
Seven IPF Experts Named to NuMedii Advisory Board

Mathew Shanley

Earlier this week, NuMedii, Inc. announced the official formation of an Idiopathic Pulmonary Fibrosis (IPF) Advisory Board.

The newly created Board of Advisors will seek to provide deep scientific and clinical expertise to the company as it discovers and advances new treatments for IPF, based on NuMedii's Artificial Intelligence for Drug Discovery (AIDD) technology.

IPF is a progressive, life-threatening disease with poor prognosis in which the replacement of small air sacs of the lung with fibrotic tissue causes the gradual worsening of dyspnea. The condition is characterized by common symptoms like shortness of breath; fatigue; dry, hacking cough; and shallow breathing.

By partnering information from basic human biology that consists of both insights from literature and molecular, pharmacological and clinical data points with proprietary machine learning and network-based algorithms, NuMedii’s AIDD technology seeks to discover and advance precise, effective new drug candidates, and biomarkers predictive of efficacy for subsets of patients in IPF and other rare diseases.

"We are thrilled to assemble such a distinguished group of experts in IPF on our Advisory Board," said Gini Deshpande, Ph.D., chief executive officer, NuMedii, Inc. in a press release. "The formation of our IPF Advisory Board and our achievement in building our proprietary knowledge base for IPF ahead of schedule reflects our steadfast commitment to this rare disease. We thank all our IPF Advisors for their dedication, as their unparalleled insights and experiences will be invaluable to NuMedii as we continue to further advance our work in IPF, a horrible lung disease for which there remains significant unmet medical need." 

Among the experts who have been named to the new Board of Advisors are:
 
NuMedii continues to cultivate AIDD technology at Stanford University, and has active research and development collaborations with several global pharmaceutical and biotech companies and patient-focused organizations to create pipeline and new products in multiple therapeutic areas including rare diseases.

For more from companies looking to impact the rare disease community, follow Rare Disease Report on Facebook and Twitter.

To get rare disease news sent straight to your inbox, sign up for our e-newsletter.
 
Printer Printing...
$content$